What were the key highlights for Anteris Technologies (ASX:AVR) in Q1 2026?

Anteris Technologies reported a transformative quarter defined by a US$320 million aggregate capital raise completed in January 2026. This massive injection of capital is designed to support the execution of the PARADIGM Trial and move the company closer to the global commercialization of its DurAVR® THV system.

Why is the US$320 million capital raise significant for Anteris Technologies (ASX:AVR) investors?

The US$320 million raise significantly de-risks the company’s commercial pathway by providing the necessary runway to advance the DurAVR® THV system toward market launch. Large capital raises in the biotech sector often suggest institutional confidence but can also result in share dilution for existing retail holders.

What is the current status of the Anteris PARADIGM Trial?

The PARADIGM Trial is currently seeing "strong execution" with ongoing patient enrolment across Europe and recent commencement in the United States. Clinical centers are progressing through essential milestones, including regulatory approvals and site initiation visits.

How does the recent Medicare (CMS) ruling impact Anteris Technologies (ASX:AVR)?

The Centers for Medicare and Medicaid Services (CMS) issued a coverage determination that facilitates patient recruitment by ensuring procedures at U.S. study sites are eligible for reimbursement. Specifically, procedures are covered under the Transcatheter Aortic Valve Replacement (TAVR) National Coverage Determination 20.32.

What clinical data has Anteris Technologies (ASX:AVR) recently released?

During the quarter, Anteris presented clinical data from its ongoing EMBARK Study and U.S. Early Feasibility Study (EFS). These results were shared at major industry events, including Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026.

Anteris Technologies propels heart valve trials with $320M

Written by Isaac FrancisPublished May. 13 2026Last Updated May. 13 2026

Anteris Technologies Global (ASX:AVR) recorded its first quarter for 2026, headlined by a US$320 million aggregate capital raise in January that has de-risked the commercial pathway for its flagship DurAVR THV system.

The structural heart specialist confirmed that its pivotal PARADIGM trial is gaining substantial momentum following the commencement of patient enrolment in the United States.

The expansion into the US market, supported by recent coverage determinations from the Centres for Medicare and Medicaid Services, ensures that eligible procedures at participating study sites are now covered under National Coverage Determination 20.32 for Transcatheter Aortic Valve Replacement.

CEO Wayne Paterson highlighted the company’s "strong execution", noting that site initiation visits and investigator training are advancing rapidly across Europe and North America.

Beyond the pivotal trial, Anteris continues to build a robust scientific portfolio, recently presenting new data from the EMBARK study and US early feasibility study at major cardiovascular conferences in both Sydney and the United States.

The dual-listed firm, headquartered in Brisbane and Minneapolis, remains focused on completing trial milestones as additional clinical centres come online to contribute to the growing enrolment trajectory for the remainder of the 2026 fiscal year.

At the time of reporting, Anteris Technologies Global's share price was $8.80.